Ascendiant Capital Markets Predicts RenovoRx Q1 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Analysts at Ascendiant Capital Markets lifted their Q1 2027 earnings per share (EPS) estimates for RenovoRx in a research report issued to clients and investors on Saturday, November 7th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.06) per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for RenovoRx’s current full-year earnings is ($0.28) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q4 2027 earnings at ($0.03) EPS.

Several other equities research analysts also recently weighed in on RNXT. Weiss Ratings upgraded shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. Wall Street Zen lowered RenovoRx from a “hold” rating to a “sell” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.

RenovoRx Stock Up 3.4%

Shares of RenovoRx stock opened at $1.22 on Thursday. The company has a market cap of $58.87 million, a P/E ratio of -3.94 and a beta of 1.12. The firm’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.11. RenovoRx has a 52-week low of $0.70 and a 52-week high of $2.59.

RenovoRx (NASDAQ:RNXT) last announced its earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.06 million.

Institutional Investors Weigh In On RenovoRx

A hedge fund recently raised its stake in RenovoRx stock. State Street Corp increased its stake in shares of RenovoRx, Inc. (NASDAQ:RNXT) by 501.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 314,636 shares of the company’s stock after buying an additional 262,332 shares during the quarter. State Street Corp owned about 0.65% of RenovoRx worth $491,000 as of its most recent SEC filing. Institutional investors own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.